Prenatal hormonal therapy improves pulmonary compliance in the nitrofen-induced CDH rat model.
Neonates with congenital diaphragmatic hernia (CDH) experience a high mortality despite intensive medical and surgical management. The associated pulmonary hypoplasia is accompanied by an underlying biochemical deficiency that bears similarity to respiratory distress syndrome (RDS) in the premature newborn. Using therapies extrapolated from those used to treat RDS, the authors have previously shown correction of the immature pulmonary biochemical indices in the nitrofen rat CDH model. This study investigates the functional and histological outcome of prenatal hormone therapy on CDH rats. Compared with saline-treated CDH controls, dexamethasone-treated CDH animals achieved significant increases in lung distensibility (P = .0006) and functional residual capacity (P = .004); CDH rats treated with combined dexamethasone and thyrotropin-releasing hormone (TRH) showed improved functional residual capacity (P = .043) and alveolar stability (P = .025); CDH animals treated with TRH alone (TRH-CDH) showed no improvement in any parameter tested. Histologically, the lungs from dexamethasone- and dexamethasone-TRH-treated CDH animals showed changes that included narrow septal walls, increased air saccule size, and thinning of the pulmonary interstitium compared with the lungs of saline or TRH-CDH rats, which were developmentally arrested at the canalicular stage. Lung weights and lung weight-body weights ratios were similar in all CDH rats, confirming that treatment did not impair pulmonary growth. These results support the potential clinical use of prenatal pharmacological therapies to treat human fetuses with prenatally diagnosed CDH.
Losty
P D
PD
Pediatric Surgical Research Laboratories, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA.
Suen
H C
HC
Manganaro
T F
TF
Donahoe
P K
PK
Schnitzer
J J
JJ
D000818:Animals; D003907:Dexamethasone / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006548:Hernia, Diaphragmatic / Q000139:chemically induced / Q000150:complications; D065630:Hernias, Diaphragmatic, Congenital; D006801:Humans; D007231:Infant, Newborn; D008168:Lung / Q000196:embryology; D008170:Lung Compliance / Q000187:drug effects; D010647:Phenyl Ethers; D051381:Rats; D017207:Rats, Sprague-Dawley; D012127:Respiratory Distress Syndrome, Newborn / Q000503:physiopathology / Q000517:prevention & control*; D015656:Respiratory Mechanics / Q000502:physiology; D013973:Thyrotropin-Releasing Hormone / Q000627:therapeutic use*
D010647:Phenyl Ethers; D013973:Thyrotropin-Releasing Hormone; D003907:Dexamethasone; C007350:nitrofen